Core Viewpoint - Beijing Puxi Pharmaceutical Technology Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange after withdrawing its IPO application from the Beijing Stock Exchange, reflecting a strategic shift for unprofitable biotech companies in the current market environment [1][3][6] Company Overview - Puxi Pharmaceutical, established in 2016, focuses on the field of immune inflammation, with its core product being Pumeixin (PG-011) [3][6] - The company has not yet launched any products, with its core product currently in various stages of clinical trials [1][3] Financial Performance - The company reported a cumulative loss exceeding 300 million yuan from 2024 to the first three quarters of 2025, with a net loss of 178.496 million yuan for 2024 and 125 million yuan for the first three quarters of 2025 [2][6] - Puxi Pharmaceutical's revenue was zero for 2022 and 2023, with only 47,200 yuan in revenue from other business activities in 2024 [5][6] Strategic Shift - The decision to switch from the Beijing Stock Exchange to the Hong Kong Stock Exchange is seen as a pragmatic adjustment due to the more stringent review process for unprofitable companies on the former [1][6] - The Hong Kong Stock Exchange's Chapter 18A is designed for unprofitable biotech companies, offering lower listing thresholds and faster access to capital [1][6] Product Development - Pumeixin has two formulations: a gel for atopic dermatitis and a nasal spray for allergic rhinitis, both of which are in advanced clinical trial stages [7][8] - The gel has completed Phase III trials for adults and adolescents, while the nasal spray is in Phase III trials for adults [7] Commercial Collaboration - Puxi Pharmaceutical has signed an exclusive commercialization agreement with Jichuan Pharmaceutical, allowing the latter to market Pumeixin nasal spray in China for up to 1 billion yuan [8][9] - This partnership is expected to provide essential funding and leverage Jichuan's commercial expertise to expedite market entry for Puxi's products [9]

Core Viewpoint - As of January 30, 2026, the number of common stock shareholders for Zhifei Biological Products Co., Ltd. (stock code: 300122) is reported to be 128,281 [1] Company Summary - Zhifei Biological Products Co., Ltd. has engaged with investors through an interactive platform, providing transparency regarding its shareholder base [1]

Group 1 - The company, ShenZhou Cell, has received approval for a private placement registration as of January 2026, allowing it to issue shares worth up to 900 million RMB [2] - The controlling shareholder plans to subscribe for no more than 900 million RMB of the company's shares [2] - The company intends to initiate and complete the issuance as soon as possible, with further updates to be provided in subsequent announcements [2]

Core Viewpoint - The sales of Anjiahin® are expected to decline significantly by 2025 due to several factors, including medical insurance cost control and substantial price reductions initiated by the company in response to national healthcare policies [1] Group 1: Sales and Market Impact - The decline in Anjiahin® sales is primarily influenced by the reduction in patient usage resulting from medical insurance cost control measures [1] - Starting from the third quarter of 2025, Anjiahin® will undergo significant price cuts to align with the national healthcare bureau's initiatives, aiming to make the medication more accessible to patients [1] Group 2: Treatment Guidelines and Patient Care - The revised "Chinese Guidelines for Hemophilia Treatment (2025 Edition)" has redefined treatment approaches for coagulation disorders, shifting from traditional preventive treatment to regular replacement therapy and from on-demand treatment to temporary replacement therapy [1] - The medical community is emphasizing the importance of preventive treatment, and the company hopes that adult patients will receive similar protections as pediatric patients [1] - The company anticipates that the recombinant factor VIII will receive equal treatment as blood-derived factor VIII in the future [1]

Core Viewpoint - Zhifei Biological has received approval from the National Medical Products Administration for clinical trials of its recombinant varicella-zoster virus vaccine (ZFA01) in individuals aged 40 and above, marking a significant advancement in its innovative adjuvant technology platform [1] Group 1: Company Developments - The clinical trial approval for the ZFA01 vaccine is a result of the company's focus on innovation and strengthening core technological capabilities [1] - Successful progress of this project is expected to enrich the company's adult vaccine portfolio and enhance its product layout [1] - The development of this vaccine will further solidify the company's market position in the vaccine industry [1]

Core Viewpoint - Yuan Dong Bio (688513) announced that its wholly-owned subsidiary Chengdu Youluo Biotechnology Co., Ltd. has initiated Phase I clinical trials for its monoclonal antibody EP-0210 injection, targeting inflammatory bowel disease, with the first patient dosing recently completed [1] Company Summary - EP-0210 is a humanized IgG1 monoclonal antibody that targets TNF-like ligand 1A (TL1A), aiming to treat inflammatory bowel disease by effectively binding to TL1A and blocking pro-inflammatory signaling pathways [1] - The development of TL1A antibody drugs is one of the most closely watched emerging targets in the field of inflammatory bowel disease, with no similar drugs currently available on the market globally [1] Industry Summary - The fastest global development progress for TL1A-targeting drugs is being made by Merck, Sanofi, and Roche/Pfizer, all of which have TL1A antibody drugs in Phase III clinical trials [1] - In China, companies such as 3SBio, ZhiXiang JinTai, and HuaShen ZhiYao have also entered Phase I clinical trials for similar TL1A-targeting drugs [1]

Group 1 - The core viewpoint of the article highlights a significant decline in sales of the product Anjiaan® in 2025, attributed to several factors including medical insurance cost control leading to reduced patient usage [2] - The company has implemented a substantial price reduction for Anjiaan® starting from the third quarter of 2025 in response to the National Medical Insurance Administration's call, aiming to benefit patients and improve their survival conditions [2] - The revised "Guidelines for the Treatment of Hemophilia in China (2025 Edition)" has redefined treatment approaches for coagulation disorders, emphasizing the importance of preventive treatment and calling for better protection for adult patients similar to that of children [2]

Group 1 - The core viewpoint of the article highlights that the company, ShenZhou Cell, plans to invest approximately 83 million to 87 million yuan in research and development (R&D) by 2025 [2] - The company is currently in a growth phase, and maintaining high R&D investment is essential for its future development, which is a common characteristic among innovative drug development companies [2] - As multiple projects progress into mid-to-late clinical research stages, the company's R&D expenditures are expected to remain elevated [2]

相关委任获股东于股东特别大会上批准后，康睿女士已获委任为非执行董事及金腾川教授已获委任为独 立非执行董事，执行董事兼总裁陈鹏先生已获委任为主席，陈正永先生不再担任主席，惟仍将担任执行 董事;均自2026年2月9日起生效。 中生北控生物科技(08247)公布，由于杨鹏先生、高光侠博士、沈胜博士、沈佐君教授及何欣博士的董 事任期已于股东特别大会上届满且彼等均因希望投入更多时间在其他事务而不愿意接受重新委任，(a) 杨鹏先生、高光侠博士、沈胜博士均不再担任非执行董事;(b)沈佐君教授不再担任独立非执行董事、薪 酬委员会主席、审核委员会及提名委员会各自的成员;及(c)何欣博士不再担任独立非执行董事、审核委 员会、提名委员会及薪酬委员会各自的成员，均自2026年2月9日起生效。 ...

（来源：药研网） 2025年2月9日，据CDE官网公示，信达生物已递交其1类新药IBI115的临床试验（IND）申请。 | | | 日 | | | | | --- | --- | --- | --- | --- | --- | | CXSL2600186 | IBI115 | 治疗用 生物制 | 新药 | 信达生物制药（苏州）有限公司; | 2026-02- 09 | 据公开资料，IBI115 是一款DLL3/CD3双特异性抗体药物，通过同时连接 T 细胞（通过 CD3）和肿瘤细胞（通过 DLL3），激活 T 细胞识 别并杀伤肿瘤细胞。 | ) 新药情报库 | 产品 > 数据 √ | 资源 √ | 版本对比 | Q 搜索药物、靶点、适应症、机构 ... | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | IBI115 | | | | | | | | | 概要 研发状态 | 临床结果 转化医学 | 药物交易 | 核心专利 | 临床分析 | 批准 | 生物类似药 | 特殊审评 | | 概要 | | | | | | | | | 基本信息 | | | ...